

PRIOR AUTHORIZATION CRITERIA

| DRUG CLASS | TESTOSTERONE PRODUCTS |
|--|--|
| BRAND NAME (generic) | ANDRODERM (testosterone transdermal patch) |
| | ANDROGEL (testosterone topical gel) |
| | DELATESTRYL (testosterone enanthate injection) |
| | DEPO-TESTOSTERONE (testosterone cypionate injection) |
| | FORTESTA (testosterone topical gel) |
| | JATENZO (testosterone undecanoate oral) |
| | KYZATREX (testosterone undecanoate oral) |
| | NATESTO (testosterone nasal gel) |
| | TESTIM (testosterone topical gel) |
| | TESTOPEL (testosterone propionate implant pellets) |
| | (testosterone topical solution) |
| | TLANDO (testosterone undecanoate oral) |
| | VOGELXO (testosterone topical gel) |
| XYOSTED (testosterone enanthate) | |

Status: CVS Caremark Criteria
Type: Initial Prior Authorization

POLICY

FDA-APPROVED INDICATIONS

Androderm, AndroGel, Fortesta, Natesto, Testim, testosterone topical solution, Vogelxo

Topical, nasal, and injectable testosterone products are indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone:

- Primary hypogonadism (congenital or acquired): testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (FSH, LH) above the normal range.
- Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum concentrations but have gonadotropins in the normal or low range.

Limitations of Use

- Safety and efficacy of topical, nasal, and injectable testosterone products in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established.
- Safety and efficacy of topical, nasal, and injectable testosterone products in males less than 18 years old have not been established.
- Topical testosterone products may have different doses, strengths or application instructions that may result in different systemic exposure.

Depo-Testosterone

Depo-Testosterone Injection is indicated for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone.

1. Primary hypogonadism (congenital or acquired)-testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchiectomy.
2. Hypogonadotropic hypogonadism (congenital or acquired)- gonadotropic or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma or radiation.

Safety and efficacy of Depo-Testosterone (testosterone cypionate) in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established.

Jatenzo, Kyzatrex, Tlando

Testosterone undecanoate is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone:

- Primary hypogonadism (congenital or acquired): testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle stimulating hormone (FSH), luteinizing hormone (LH)) above the normal range.
- Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum concentrations but have gonadotropins in the normal or low range.

Limitations of Use

Safety and efficacy of testosterone undecanoate in males less than 18 years old have not been established.

**Testopel
Males**

Androgens are indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone.

- a. Primary hypogonadism (congenital or acquired) - testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testes syndrome; or orchiectomy.
- b. Hypogonadotropic hypogonadism (congenital or acquired) - gonadotropic LHRH deficiency, or pituitary - hypothalamic injury from tumors, trauma or radiation.

If the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sex characteristics. Prolonged androgen treatment will be required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty.

Safety and efficacy of Testopel (testosterone pellets) in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established.

- c. Androgens may be used to stimulate puberty in carefully selected males with clearly delayed puberty. These patients usually have a familial pattern of delayed puberty that is not secondary to a pathological disorder; puberty is expected to occur spontaneously at a relatively late date. Brief treatment with conservative doses may occasionally be justified in these patients if they do not respond to psychological support. The potential adverse effect on bone maturation should be discussed with the patient and parents prior to androgen administration. An x-ray of the hand and wrist to determine bone age should be taken every 6 months to assess the effect of treatment on epiphyseal centers.

Testosterone Enanthate Injection

Males

Testosterone Enanthate Injection (generic Delatestryl), USP is indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone.

Primary hypogonadism (congenital or acquired) - testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, or orchiectomy.

Hypogonadotropic hypogonadism (congenital or acquired) - gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. (Appropriate adrenal cortical and thyroid hormone replacement therapy are still necessary, however, and are actually of primary importance).

If the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sexual characteristics. Prolonged androgen treatment will be required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty.

Safety and efficacy of Testosterone Enanthate Injection (generic Delatestryl), USP in men with age-related hypogonadism have not been established.

Delayed puberty - Testosterone Enanthate Injection (generic Delatestryl), USP may be used to stimulate puberty in carefully selected males with clearly delayed puberty. These patients usually have a familial pattern of delayed puberty that is not secondary to a pathological disorder; puberty is expected to occur spontaneously at a relatively late date. Brief treatment with conservative doses may occasionally be justified in these patients if they do not respond to psychological support. The potential adverse effect on bone maturation should be discussed with the patient and parents prior to androgen administration. An X-ray of the hand and wrist to determine bone age should be obtained every six months to assess the effect of treatment on the epiphyseal centers.

Females

Metastatic mammary cancer - Testosterone Enanthate Injection (generic Delatestryl), USP may be used secondarily in women with advancing inoperable metastatic (skeletal) mammary cancer who are one to five years postmenopausal.

Primary goals of therapy in these women include ablation of the ovaries. Other methods of counteracting estrogen activity are adrenalectomy, hypophysectomy, and/or anti-estrogen therapy. This treatment has also been used in pre-menopausal women with breast cancer who have benefited from oophorectomy and are considered to have a hormone-responsive tumor. Judgment concerning androgen therapy should be made by an oncologist with expertise in this field.

Xyosted

Xyosted (testosterone enanthate) injection is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.

- Primary hypogonadism (congenital or acquired): testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter’s syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range.

- Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum concentrations but have gonadotropins in the low or normal range.

Limitations of Use:

- Safety and efficacy of Xyosted in males less than 18 years old have not been established.

Compensial Uses

Gender Dysphoria^{16-18,20-22} (also known as transgender and gender diverse (TGD) persons)

COVERAGE CRITERIA

The requested drug will be covered with prior authorization when the following criteria are met:

- The requested drug is NOT being prescribed for “age-related hypogonadism” (also referred to as “late-onset hypogonadism”)

AND

- The requested drug is being prescribed for primary or hypogonadotropic hypogonadism

AND

- The request is NOT for continuation of therapy

AND

- Before the start of testosterone therapy, the patient has at least two confirmed low morning testosterone levels according to current practice guidelines or your standard lab reference values

OR

- The request is for continuation of therapy

AND

- Before the patient started testosterone therapy, the patient had a confirmed low morning testosterone level according to current practice guidelines or your standard lab reference values

OR

- The requested drug is being prescribed for gender dysphoria in a patient who is able to make an informed decision to engage in hormone therapy

AND

- The patient’s comorbid conditions are reasonably controlled

AND

- The patient has been educated on any contraindications and side effects to therapy

AND

- Before the start of therapy, the patient has been informed of fertility preservation options

AND

- If the patient is less than 18 years of age,

AND

- The requested drug is prescribed by or in consultation with a provider specialized in the care of transgender youth (e.g., pediatric endocrinologist, family or internal medicine physician, obstetrician-gynecologist), that has collaborated care with a mental health provider

AND

- The patient has reached, or has previously reached, Tanner stage 2 of puberty or greater

OR

- The request is for intramuscular testosterone enanthate injection (generic Delatestryl)

AND

- The requested drug is being prescribed for inoperable metastatic breast cancer in a patient who is 1 to 5 years postmenopausal and had an incomplete response to other therapy for metastatic breast cancer

OR

- The requested drug is being prescribed for a premenopausal patient with breast cancer who has benefited from oophorectomy and is considered to have a hormone-responsive tumor

OR

- The requested drug is being prescribed for delayed puberty

OR

- The request is for testosterone propionate implant pellets (Testopel)
AND
 - The requested drug is being prescribed for delayed puberty

REFERENCES

1. Androderm [package insert]. Madison, NJ: Allergan USA, Inc.; May 2020.
2. Androgel 1% [package insert]. North Chicago, IL: Abbvie Inc.; May 2019.
3. Androgel 1.62% [package insert]. North Chicago, IL: Abbvie Inc.; November 2020.
4. Depo-Testosterone [package insert]. New York, NY: Pharmacia and Upjohn Co; September 2018.
5. Fortesta [package insert]. Malvern, PA: Endo Pharmaceuticals Inc.; January 2022.
6. Jatenzo [package insert]. Northbrook, IL: Clarus Therapeutics, Inc.; June 2019.
7. Kyzatrex [package insert]. Raleigh NC: Marius Pharmaceuticals LLC; July 2022.
8. Natesto Nasal Gel [package insert]. Mississauga, ON: Acerus Pharmaceutical Corporation; December 2021.
9. Testim [package insert]. Malvern, PA: Endo Pharmaceuticals Inc.; August 2021.
10. Testopel (testosterone pellets) [package insert]. Malvern, PA: Endo Pharmaceuticals Inc.; August 2018.
11. Testosterone Enanthate Injection [package insert]. Berkley Heights, NJ: Hikma Pharmaceuticals USA Inc.; January 2021.
12. Testosterone Topical Solution [package insert]. Bedminster, NJ: Alembic Pharmaceuticals, Inc.; December 2022.
13. Tlando [package insert]. Ewing, NJ: Antares Pharma, Inc.; March 2022.
14. Vogelxo [package insert]. Maple Grove, MN: Upsher-Smith Laboratories, LLC; April 2020.
15. Xyosted [package insert]. Ewing, NJ: Antares Pharma, Inc.; November 2019.
16. Lexicomp Online, AHFS DI (Adult and Pediatric) Online, Hudson, Ohio: UpToDate, Inc.; 2023; Accessed January 26, 2023.
17. Lexicomp Online, Lexi-Drugs Online, Hudson, Ohio: UpToDate, Inc.; 2023; Accessed January 26, 2023.
18. Micromedex (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. Available at: <https://www.micromedexsolutions.com>. Accessed January 26, 2023.
19. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab*. 2018;103(5):1715-1744.
20. Coleman E, Radix AE, Bouman WP, et al. Standards of Care for the Health of Transgender and Gender Diverse People, Version 8. *Int J Transgend Health*. 2022;23(S1):S1-S258.
21. Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine Treatment of Gender Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab*. 2017;102(11):3869-3903.
22. Health Care for Transgender and Gender Diverse Individuals. ACOG Committee Opinion No. 823. American College of Obstetricians and Gynecologists. *Obstet Gynecol*. 2021;137:e75-88.